Top Sector Life Sciences & Health (LSH) entails a broad scope of disciplines, from pharmaceuticals to medical technology and from healthcare infrastructure to vaccination. To realise its mission – vital citizens in a healthy economy - the Top Sector builds on the strengths of the Dutch LSH sector to address the biggest societal challenges in prevention, cure and care. By funding multidisciplinary public-private partnerships (PPPs) the Top Sector aims to facilitate innovation. Here we give an overview of  a number of funded R&D projects by Top Sector LSH. The page is updated continuously.

Sarcoma imaging: from improving clinical care towards decoding tumour phenotype

Multimodality imaging for personalising sarcoma care (MULTIPLE)

In this project, researchers at the Leiden University Medical Centre (LUMC) are investigating on how quantitative medical imaging can assist in personalising treatment of patients with soft tissue and bone cancers. Individualising treatment has a great potential to further maximise treatment effect and reduce unnecessary side effects and cost associated with these treatments. The LUMC is collaborating closely with Philips Healthcare in order to ensure that latest imaging technologies and analysis tools can be used in this research.

In clinical practice, selection of optimal treatment is difficult for these patients, given that there are more than 50 distinct types of sarcoma. Furthermore, as much as 20% of these patients are below 40 years. This emphasises the importance of saving patients from debilitating surgeries, employing strategies to operate sparingly whilst still removing the entire tumour, and avoid toxicity from ineffective chemo- and or radiotherapy. Employing personalised medicine for these patients has the potential to improve patient outcome and quality of life.

The researcher at the LUMC will investigate the value of quantitative medical imaging for measuring biological processes (e.g. glucose metabolism, water diffusion, perfusion) in the tumour to identify patients at risk of disease recurrence. Furthermore, the change in these characteristics over time will be correlated with effectiveness of chemo- and or radiotherapy. 

The combined information from different imaging modalities (such as PET, CT, and MRI scans) will be used to create models that can predict clinical course of these patients. Improved knowledge whether patients benefit from specific treatments or require additional treatment before or after surgery. Eventually such models can be employed in clinical practice, where imaging data can provide an integrate role in improved clinical decision making.